The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
CREDIT DESIGNATION STATEMENT
The AACR has designated this live activity for a maximum of 15.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
CLAIMING (CME) CREDIT
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the online CME Request for Credit Survey (available here as the meeting approaches). Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.
STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE AND LEARNING OBJECTIVES
While advances in the prevention, detection, and treatment of breast cancer have made tremendous strides in the last 20 years, breast cancer is still the second most common cancer among women (only behind skin cancers) and the second leading cause of cancer deaths among women (only behind lung cancer). In 2012, an estimated 39,510 women will die from breast cancer (American Cancer Society: Breast cancer detailed guide). The fields of research being presented at this conference are rapidly advancing our knowledge base and will guide the development of more effective (and less toxic) treatments for breast cancer. Gene expression analysis has led to the identification of distinct sub-types of breast cancer, allowing for the development of more targeted therapies based on the patient’s individual tumor. Studies into the body’s immune system are leading to promising developments in vaccines that have the potential to recognize and kill cancer cells (National Cancer Institute). This conference typically attracts 300-400 basic, clinical, physicians-scientists and translational breast cancer researchers from around the world. Attending this program will not only provide them with the latest research in the fields above, but also help build collaborations to advance the detection, prevention, and treatment of this disease. Clinicians will leave this program with additional knowledge in the fields of genomics, epigenomics, tumor dormancy and metastasis which all have direct correlations to detection and patient care. Discussions on targeted therapies will guide future decisions on potential treatments based on the numerous breast cancer subtypes now identified.
After participating in this CME activity, physicians should be able to:
- Interpret genomic and epigenomic research findings into potentially clinically-relevant information for patients;
- Assess the current state of stem cell research and its application to breast cancer initiation and progression;
- Evaluate the latest in therapies targeted for specific breast cancer subtypes and/or pathways; and
- Explain the roles of the tumor microenvironment, tumor dormancy and metastasis in breast cancer progression.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
ACKNOWLEDGEMENT OF FINANCIAL OR OTHER SUPPORT
This activity is supported by grants and will be disclosed at the activity.
QUESTIONS ABOUT CME?
Please contact the Office of CME at (215) 440-9300 or email@example.com.